Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.

摘要: Abstract Five patients from the Kyushu area in Japan with adult T-cell leukaemia (ATL) refractory to conventional chemotherapeutic agents were treated 5 mg/m 2 of adenosine deaminase inhibitor, 2′-deoxycoformycin (DCF), intravenously (i.v.) for 3 consecutive days, followed by i.v. weekly. Two showed a good response, and three resistant DCF. One patient ATL receiving DCF had continuous remission without further therapy. Another terminal stage received daily injections 7.5 mg The most prominant change was drop leucocyte count. cell count fell 116.4 × 10 9 /1 2.0 on day 7. only adverse effects therapy gastrointestinal toxicity, nausea vomiting. These results suggest that may be valuable drug treating ATL.